BillionToOne

Historical price data

BillionToOne is a commercial-stage precision diagnostics company with a mission to remove the fear of the unknown by providing accurate, fast, and accessible molecular diagnostics. The company has achieved significant milestones, including a successful November 2025 IPO and the commercial launch of its UNITY prenatal and Northstar oncology liquid biopsy suites, which are built on its proprietary single-molecule NGS platform. Its strategy is to dominate high-growth segments in prenatal screening and oncology by leveraging its unique ability to quantify sparse DNA fragments with single-molecule precision, thereby addressing critical unmet needs in early disease detection and monitoring.

Proprietary single-molecule next-generation sequencing (smNGS) platform enabled by Quantitative Counting Templates™ (QCTs™) for absolute quantification of target DNA molecules with single base-pair resolution.

In prenatal testing, BillionToOne's UNITY suite is differentiated by its unique ability to screen for single-gene conditions, a feature not offered by major NIPT players like Natera or Roche. In oncology, its Northstar suite competes on superior sensitivity (0.01% VAF) against liquid biopsy leaders like Guardant Health and FOUNDATION Medicine, targeting the niche of low-shedding tumors and precise monitoring.